Phenylpiperazine derivatives: a patent review (2006 – present)

Bibliography

• Lopez-Rodriguez ML, Ayala D, Benhamu B, Arylpiperazine derivatives acting at 5-HT(1A) receptors. Curr Med Chem 2002;9:443-69
   PubMed Web of Science ®Google Scholar
• Rosini M, Bolognesi ML, Giardina D, Recent advances in alpha1-adrenoreceptor antagonists as pharmacological tools and therapeutic agents. Curr Top Med Chem 2007;7:147-62
   PubMed Web of Science ®Google Scholar
• SosKic V, Joksimovic J. Bioisosteric approach in the design of new dopaminergic/serotonergic ligands. Curr Med Chem 1998;5:493-512
   PubMed Web of Science ®Google Scholar
• Pigott TA, Carson WH, Saha AR, Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-56
   PubMed Web of Science ®Google Scholar
• Marder SR, McQuade RD, Stock E, Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-6
   PubMed Web of Science ®Google Scholar
• Burris KD, Molski TF, Xu C, Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-9
   PubMed Web of Science ®Google Scholar
• Cusack B, Nelson A, Richelson E. Binding of Antidepressants to Human Brain Receptors: focus on Newer Generation Compounds. Psychopharmacology (Berl) 1994;114:559-65
   PubMed Web of Science ®Google Scholar
• Lacivita E, Leopoldo M, De Giorgio P, Determination of 1-aryl-4-propylpiperazine pKa values: the substituent on aryl modulates basicity. Bioorg Med Chem 2009;17:1339-44
   PubMed Web of Science ®Google Scholar
• Schering Corp. Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity. WO088919; 2006
   Google Scholar
• Laboratorios Del Dr. Esteve S/A. Substituted phenyl-piperazine compounds, their preparation and use in medicinal chemistry. WO069807; 2006
   Google Scholar
• Laboratorios Del Dr. Esteve S/A. Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicinal chemistry. WO069808 ; 2006
   Google Scholar
• Abbot Laboratories. N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor. WO125134; 2010
   Google Scholar
• SK Holdings CO. Phenyl piperazine compounds, pharmaceutical compositions including the same, and use therof. WO145591; 2009
   Google Scholar
• Ache Laboratorios Farmaceuticos S.A. Compounds and pharmaceutical compositions for treating disorders associated with the 5-HT1A and 5-HT2A receptors. WO037634; 2012
   Google Scholar
• H. Lundbeck A/S. New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)- phenyl]piperazine and pharmaceutical acceptable acid addition salts thereof adapted so that release does not take place in the stomach is provided. WO023194; 2011
   Google Scholar
• H. Lundbeck A/S. Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)- phenyl]piperazine. WO025123; 2012
   Google Scholar
• Universidade Federal do Rio de Janeiro-UFRJ. Use of N-phenylpiperazine derivatives and pharmaceutical compositions containing them. WO024121; 2006
   Google Scholar
• Solvay Pharmaceuticals B.V. Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition. WO061379; 2006
   Google Scholar
• Solvay Pharmaceuticals B.V. Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition. WO061377; 2006
   Google Scholar
• Richter Gedeon Nyrt. Novel piperazine salts as D3/D2 antagonists. WO139235; 2008
   Google Scholar
• F. Hoffman-LA Roche AG. Arylpiperazine derivatives and uses thereof. WO019971; 2008
   Google Scholar
• Otsuka Pharmaceutical CO. Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine. WO036253; 2012
   Google Scholar
• SK Holdings CO. Phenyl piperazine compounds, pharmaceutical composition comprising the same, and use thereof. WO145590; 2009
   Google Scholar
• Glaxo Group Limited. Piperazine derivatives as GLYT1 inhibitors. WO094843; 2006
   Google Scholar
• Amgen Inc. Glycine transporter-1 inhibitors. WO075857; 2009
   Google Scholar
• Janssen Pharmaceutica N.V. Piperidinyl and piperazinyl modulators of gamma-secretase. WO052126; 2009
   Google Scholar
• Helicon Therapeutics, inc. Therapeutic piperazines as PDE4 inhibitors. WO100852; 2007
   Google Scholar
• SK Holdings CO. Novel carbamoyloxy aryl alkan arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound. WO140197; 2008
   Google Scholar
• Eli Lilly and Co. Substituted piperazinyl pyrazines and pyridines as 5-HT7 receptor antagonists. WO029439; 2009
   Google Scholar
• Glaxo Group, Ltd. 4-Benzoyl-1-substituted-piperazin-2-one derivatives as P2X7 modulators. WO053459; 2009
   Google Scholar
• Astrazeneca UK, Ltd. Piperazine compounds useful as antagonists of C-C chemokines (CCR2 and CCR5) for the treatment of inflammatory diseases. WO 071952; 2007
   Google Scholar
• Schering, Corp. Substituted piperazines as CB1 antagonists. WO060461 ;2006
   Google Scholar
• Vernalis (R & D), Ltd. Piperazine derivatives and their use in therapy. WO057687; 2007
   Google Scholar
• Schering, Corp. Substituted piperazines as CB1 antagonists. WO005646; 2009
   Google Scholar
• F. Hoffman-LA Roche AG. Novel piperazine amides derivatives. WO021868; 2009
   Google Scholar
• Takeda Pharmaceutical Company, Ltd. Derivatives of N-acyl-N’-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes. WO119992; 2010
   Google Scholar
• Wyeth LLC. 11-BETA HSD1 inhibitors. WO141550; 2010
   Google Scholar
• Actelion Pharmaceuticals, Ltd. Novel piperazine derivatives. WO034445; 2007
   Google Scholar
• Glaxo Group, Ltd. 1-{4- [ (1-cyclobutyl-4-piperidinyl) oxy] phenyl] -4-} [4-(methylsulfonyl) phenyl]carbonyl piperazine as histamine H3 antagonist. WO090142; 2006
   Google Scholar
• DAC SLR. A new class of histone deacetylase inhibitors. WO027395; 2009
   Google Scholar
• Janssen Pharmaceutica N.V. Novel Tricyclic dihydropyrazines as potassium channel openers. WO095424; 2007
   Google Scholar
• Romeiro LAS, Fraga CAM, Barreiro EJ. New Therapeutical Approachs for the Treatment of Depression: a Medicinal Chemistry View. Quim. Nova 2003;26:347-58
   Google Scholar
• Ritchie TJ, Macdonald SJF. The impact of aromatic ring count on compound developability – are too many aromatic rings a liability in drug design? Drug Discov Today 2009;14:1011-20
   PubMed Web of Science ®Google Scholar